Privia Health (PRVA) EBITDA (2020 - 2026)

Privia Health's EBITDA history runs 7 years deep, the most recent figure standing at $7.4 million for Q1 2026.

• On a quarterly basis, EBITDA rose 42.24% year-over-year to $7.4 million in Q1 2026; TTM through Mar 2026 was $36.4 million, a 70.46% increase from a year earlier, with the FY2025 full-year figure at $34.2 million, up 101.6% from the prior year.
• EBITDA retreated to $7.4 million in Q1 2026 per PRVA's latest filing, from $11.3 million in the prior quarter.
• Across five years, EBITDA topped out at $14.4 million in Q3 2025 and bottomed at -$11.5 million in Q1 2022.
• The 5-year median for EBITDA is $5.2 million (2025), against an average of $3.5 million.
• Across the five-year window, EBITDA sank 246.04% in 2022 and soared 534.02% in 2025, its largest moves.
• Year by year, EBITDA stood at $2.2 million in 2022, then slumped by 36.86% to $1.4 million in 2023, then surged by 269.58% to $5.2 million in 2024, then jumped by 114.9% to $11.3 million in 2025, then plunged by 34.19% to $7.4 million in 2026.
• Per Business Quant, the three latest PRVA EBITDA figures stand at $7.4 million (Q1 2026), $11.3 million (Q4 2025), and $14.4 million (Q3 2025).